Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
: Purpose: To evaluate the changes of vascular endothelial growth factor (VEGF) plasma levels after intravitreal injections of ranibizumab or bevacizumab in patients with exudative age‐related macular degeneration (AMD). Methods: Forty‐three patients with exudative AMD and 19 age‐ and sex‐matched control patients without chorioretinal diseases were studied. Nineteen patients were treated with intravitreal ranibizumab 0.5 mg, 24 with intravitreal bevacizumab 1.25 mg. Blood samples were collected just before the first injection, and 28 days after three initial consecutive injections performed in 4‐weekly intervals (loading dose). Concentration of VEGF in the plasma was measured by ELISA. Results: At baseline, the median VEGF concentrations in controls were 180.97 pg/ml, in the bevacizumab group 189.72 pg/ml and in the ranibizumab group 191.36 pg/ml. VEGF plasma concentrations in patients with wet AMD were comparable to controls (p = 0.225). Twenty‐eight days after the third injection, a significant reduction of 42% in the median VEGF plasma levels was found in bevacizumab‐treated patients (109.97 pg/ml; p = 0.0002) but not in ranibizumab‐treated patients (189.97 pg/ml; p = 0.198) where a reduction of 0.7% in the median value was found. Conclusions: Intravitreal bevacizumab significantly reduced VEGF plasma levels until 28 days after intravitreal injection in patients with exudative AMD. Ranibizumab did not achieve a significant plasma VEGF reduction at the same time‐point. These findings alert to the potential systemic safety differences between the two drugs after intravitreal administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“These results are important as VEGF is fundamental for numerous physiological extra-ocular functions, namely survival of endothelial vascular cells, neurotrophic effects and a homoeostatic factor for blood pressure and cardiovascular system (Zachary et al. 2000; Ferrara et al. 2003).”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · cited 1×
“Nevertheless, pan-VEGF inhibition with bevacizumab or ranibizumab provides the best visual results achieved so far in the treatment of neovascular AMD (Brown et al. 2006, 2009; Rosenfeld et al. 2006).”
BackgroundRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“Nevertheless, pan-VEGF inhibition with bevacizumab or ranibizumab provides the best visual results achieved so far in the treatment of neovascular AMD (Brown et al. 2006, 2009; Rosenfeld et al. 2006).”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 2×
“Although the two drugs are derived from the same very specific murine monoclonal antibody against VEGF-A, they are different concerning molecular weight, affinity to VEGF and pharmacokinetic properties (Ferrara & Kerbel 2005; Ferrara et al. 2006; Bakri et al. 2007a,b).”
BackgroundCauses and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 2×
“…Scandinavica Foundation doi: 10.1111/j.1755-3768.2011.02240.x e25 New York, NY, USA), a ribonucleic acid aptamer, which specifically binds the VEGF165 (Gragoudas et al. 2004), and ranibizumab (Lucentis ; Novartis Pharma AG, Basel, Switzerland and Genentech Inc, South San Francisco, CA, USA),…”
BackgroundInfluentialBrown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
Khan, J. C. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.073643 · Cited by 390 · cited 2×
“…risk factors such as smoking, imbalanced nutrition or hypertension that are also risk factors for arterial thromboembolic events (Goldberg et al. 1988; Christen et al. 1996; Delcourt et al. 1998; Chua et al. 2006; Khan et al. 2006; Alexander et al. 2007; Duan et al. 2007; Klein et al. 2007).”
BackgroundFACTORS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
GOLDBERG, J., FLOWERDEW, G., SMITH, E., BRODY, J. A., & TSO, M. O. M. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115023 · Cited by 384 · cited 2×
“…AMD present risk factors such as smoking, imbalanced nutrition or hypertension that are also risk factors for arterial thromboembolic events (Goldberg et al. 1988; Christen et al. 1996; Delcourt et al. 1998; Chua et al. 2006; Khan et al. 2006; Alexander et al. 2007; Duan et al. 2007; Klein…”
Background
Cited by
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Le, K., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305252 · Cited by 382
Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 352
Maguire, M. G., Daniel, E., Shah, A. R., Grunwald, J. E., Hagstrom, S. A., Avery, R. L., Huang, J., Martin, R. W., Roth, D. B., Castellarin, A. A., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.017 · Cited by 93
Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema
Stein, J. D., Newman-Casey, P. A., Kim, D. D., Nwanyanwu, K. H., Johnson, M. W., & Hutton, D. W. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.002 · Cited by 65
Metadata
- Authors
- Carneiro, Â. M., Costa, R., Falcão, M. S., Barthelmes, D., Mendonça, L. S., Fonseca, S. L., Gonçalves, R., Gonçalves, C., Falcão‐Reis, F. M., & Soares, R.
- Venue
- Acta Ophthalmologica
- Publisher
- Wiley
- Published
- 2011-09-29
- Volume
- 90
- Issue
- 1
- Pages
- e25-30
- ISSN
- 0001-639X (ISSN-L)
- 1755-375X
- 1755-3768
- OpenAlex
- W2027875367
- Cited by
- 147
- References
- 14
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab. https://app.cochat.ai/papers/10.1111/j.1755-3768.2011.02240.x
- The paper
- Carneiro, Â. M., Costa, R., Falcão, M. S., Barthelmes, D., Mendonça, L. S., Fonseca, S. L., Gonçalves, R., Gonçalves, C., Falcão‐Reis, F. M., & Soares, R. (2012). Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmologica. https://doi.org/10.1111/j.1755-3768.2011.02240.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.